Onconetix, Inc. (ONCO) stock
ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.00+0.09 (+3.09%)
Close on Nov 17, 2026Market cap $11.85MP/E –Yield –
Onconetix r&d expenses
Research and development expenses are spending on new products and technology.
Onconetix's R&D Expenses for the twelve months ending Dec 31, 2022 was $4.13M, up 211.7% year over year. For fiscal 2024 it was $154.36K, down 92.1% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $154.36K | -92.1% |
| FY2023 | Dec 31, 2023 | $1.95M | -52.8% |
| FY2022 | Dec 31, 2022 | $4.13M | +211.7% |
| FY2021 | Dec 31, 2021 | $1.33M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | $24.46K | -98.0% |
| Q3 FY2024 | Sep 30, 2024 | $109.37K | -90.7% |
| Q1 FY2024 | Mar 31, 2024 | $48.96K | -96.2% |
| Q3 FY2023 | Sep 30, 2023 | $219.24K | -51.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.21M | +175.7% |
| Q3 FY2022 | Sep 30, 2022 | $1.18M | +335.5% |
| Q2 FY2022 | Jun 30, 2022 | $1.29M | +144.3% |
| Q1 FY2022 | Mar 31, 2022 | $455.09K | +415.8% |
| Q4 FY2021 | Dec 31, 2021 | $437.33K | – |
| Q3 FY2021 | Sep 30, 2021 | $269.93K | – |
| Q2 FY2021 | Jun 30, 2021 | $529.54K | – |
| Q1 FY2021 | Mar 31, 2021 | $88.24K | – |
See a number that looks wrong?